Business
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
PARSIPPANY, N.J., November 26, 2025--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.
About this update from Zoetis Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1035,"height":387,"url":"https://media.zenfs.com/en/business-wire.com/1b1e8f12124382c7792a0e3720ecb5bf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RbPpJDu3eLMCZg2VNAWX6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1b1e8f12124382c7792a0e3720ecb5bf","width":960,"height":359},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kdu6X6ir_1dqkFtwM1OGXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNzA7aD03NzQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1b1e8f12124382c7792a0e3720ecb5bf","width":1035,"height":387}},"lazy":false},{"type":"text","content":"PARSIPPANY, N.J., November 26, 2025--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.","length":256,"tagName":"p"},{"type":"text","content":"Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of science and research, with a safety profile demonstrated in a nine-month field study where dogs receiving Lenivia experienced increased mobility and decreased pain after one injection.","length":444,"tagName":"p"},{"type":"text","content":""As pioneers in animal health innovation and veterinary monoclonal antibody development, our scientists at Zoetis are dedicated to thoroughly understanding the distinct biology of each species. This commitment fuels our discovery and development efforts to address our customers’ unmet medical needs," said Rob Polzer, Ph.D., Executive Vice President and President, Research and Development at Zoetis. "The European Commission’s marketing authorization for Lenivia marks another important step forward in managing osteoarthritis pain in dogs."","length":563,"tagName":"p"},{"type":"text","content":"Significance of OA PainOsteoarthritis is a common, chronic and progressive joint disease characterized by the inflammation and breakdown of joints, resulting in pain and mobility issues. Although...